Products
Pre-Made Efgivanermin Alfa Biosimilar, Fusion Protein targeting TNFRSF18 fused with human IGHG1 Fc (Fragment constant): Recombinant therapeutic protein targeting AITR/CD357/ENERGEN/GITR/GITR-D for drug discovery and mechanism of action (MOA) research
Cat No.: GMP-Bios-INN-815
Pre-Made Efgivanermin Alfa Biosimilar, Fusion Protein targeting TNFRSF18 fused with human IGHG1 Fc (Fragment constant): Recombinant therapeutic protein targeting AITR/CD357/ENERGEN/GITR/GITR-D is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Efgivanermin alfa is a homogenous hexameric agonist fusion protein composed of the extracellular domain (ECD) of the T-cell costimulatory receptor human glucocorticoid-induced tumor necrosis factor receptor (tumor necrosis factor superfamily, member 18; TNFRSF18; GITR) ligand (GITRL) and an immunoglobulin (Ig) G1 Fc domain, with potential immunomodulating and antineoplastic activities. Efgivanermin alfa binds to and activates GITR found on multiple types of T cells, thereby inducing both the activation and proliferation of tumor antigen-specific T-effector cells. This abrogates the suppression of T-effector cells which is induced by inappropriately activated T-regulatory cells (Tregs), suppresses Tregs and decreases Treg tumor infiltration, and activates the immune system to help eradicate tumor cells. GITR, a member of the TNF receptor superfamily, is expressed on the surface of multiple types of immune cells, including Tregs, effector T cells, B cells, dendritic cells (DCs) and natural killer (NK) cells.
Order information
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
| Catalog No. | Package | Price(In USD) | Qty (Quantity) | Sum(In USD) |
|---|---|---|---|---|
| GMP-Bios-INN-815-1mg | 1mg | 3090 | ||
| GMP-Bios-INN-815-10mg | 10mg | Inquiry | ||
| GMP-Bios-INN-815-100mg | 100mg | Inquiry | ||
| GMP-Bios-INN-815-xmg | ≥100mg | Inquiry | ||
| Shipping Cost: | 760.00 | |||
| Total: | ||||
Description
| Products Name (INN Index) | Pre-Made Efgivanermin Alfa Biosimilar, Fusion Protein targeting TNFRSF18 fused with human IGHG1 Fc (Fragment constant): Recombinant therapeutic protein targeting AITR/CD357/ENERGEN/GITR/GITR-D |
| INN Name | Efgivanermin Alfa |
| Target | TNFRSF18 |
| Format | Fusion Protein |
| Derivation | human |
| Species Reactivity | human |
| CH1 Isotype | Fusion - [IGHG1 Fc (Fragment constant) - [CORO1A (coronin 1A, actin-binding protein) - TNFSF18 (TNF superfamily member 18, AITRL, TL6, GITRL)]2]3 (hexamer) |
| VD LC | Fusion - [IGHG1 Fc (Fragment constant) - [CORO1A (coronin 1A, actin-binding protein) - TNFSF18 (TNF superfamily member 18, AITRL, TL6, GITRL)]2]3 (hexamer) |
| Highest_Clin_Trial (Jan '20) | |
| Est. Status | |
| 100% SI Structure | |
| 99% SI Structure | |
| 95-98% SI Structure | |
| Year Proposed | |
| Year Recommended | |
| Companies | MedImmune (Gaithersburg MD USA) |
| Conditions Approved | |
| Conditions Active | |
| Conditions Discontinued | |
| Development Tech | 0 |
